For the second time in a month, cancer patients were left without therapy.
Some of them told "Vijesti" that the Clinical Center (KC) lacks the cytostatic "Endoxan" and that they cannot receive chemotherapy.
"After searching the pharmacies, we were unable to find the cytostatic and we received information that it is not in stock, and that we can buy the drug in Serbia," said a family member of one of the patients.
"Montefarm", which is in charge of procurement of medicines, confirmed that they do not have "Endoxan".
"Due to the lack of raw materials at the manufacturer, we received a smaller amount of 'Endoxan', but we expect a new delivery at the end of next week", they replied to "Vijesta".
Last month, the Montenegrin health system was also left without the drug "Zometa", which is used by cancer patients with advanced disease that has affected the bones.
The reason for the shortage, as reported by "Montefarm", was a stoppage in production caused by technical problems. At the end of last month, that institution said that, according to the information they received from the manufacturer "Novartis", it is not known when they will be able to resume production.
This medicine was not even available in private pharmacies. "Zometa", claimed from "Montefarm", some private individuals have not had it since November last year. From that institution, they said that they are making efforts to obtain the necessary drug from other manufacturers and that the company "Ebewe" will deliver the drug "Zoledronate" (1 x 4 milligrams, generic parallel to "Zomete") within ten to fifteen days.
"Montefarm" announced that "Zoledronate" was delivered to them within the announced period.
A member of the patient's family, who insisted on anonymity, believes that it is a huge omission that patients are left without cytostatics, especially since they are cancer patients, who must not interrupt the therapy process. He appealed to the authorities to inform the public in such situations that there is a shortage, so that families can get medicine in the region.
Bonus video:
